-
Undiagnosed type 2 diabetes: an invisible risk factor Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-06 T, h, e, , L, a, n, c, e, t, , D, i, a, b, e, t, e, s, , &, , E, n, d, o, c, r, i, n, o, l, o, g, y
-
Bariatric tourism Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-04 T, a, l, h, a, , B, u, r, k, i
-
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-04 P, a, u, l, i, n, a, , S, a, l, m, i, n, e, n
-
Optimising zoledronate treatment holiday duration without loss of fracture prevention Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-04 M, a, t, t, h, e, w, , T, , D, r, a, k, e
-
Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass at 5 years (YOMEGA): a prospective, open-label, non-inferiority, randomised extension study Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-04 Prof Maud Robert MD, Tigran Poghosyan MD, Prof Delphine Maucort-Boulch MD, Dr Alexandre Filippello MD, Prof Robert Caiazzo MD, Adrien Sterkers MD, Lita Khamphommala MD, Prof Fabian Reche MD, Vincent Malherbe MD, Adriana Torcivia MD, Toufic Saber MD, Dominique Delaunay PhD, Carole Langlois-Jacques MSc, Augustin Suffisseau MD, Sylvie Bin MD, Prof Emmanuel Disse MD, Prof François Pattou MD
The multicentre randomised trial YOMEGA () comparing the one anastomosis gastric bypass (OAGB) with the Roux-en-Y gastric bypass (RYGB) confirmed the non-inferiority of OAGB on weight loss outcomes at 24 months. We aimed to report weight loss, metabolic, and safety outcomes at 5 years. YOMEGA is a prospective, open-label, non-inferiority, randomised trial conducted at nine centres in France. Inclusion
-
Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-04 Prof Ian R Reid MD, Anne M Horne MBChB, Borislav Mihov BPhty, Usha Bava MHSc, Angela Stewart RN, Gregory D Gamble MSc
We previously identified that zoledronate administered at 18-month intervals reduced fragility fractures by a third in a 6-year trial of women older than 65 years with osteopenia. This extension aims to identify the persistence of these effects. Of the 2000 ambulant, community dwelling, postmenopausal women older than 65 years recruited in Auckland, New Zealand, with T-scores at the total hip or femoral
-
Living between two worlds: lessons for community involvement Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-20 Ashley H Ng, Matthew Quigley, Tim Benson, Lauren Cusack, Rachel Hicks, Ben Nash, Meaghan Read, Renza Scibilia, Cheryl Steele, Leon Tribe, Elizabeth Holmes-Truscott
-
Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2023 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-20
-
Milestone achievement for global access to blood glucose meters and test strips Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-20 Emma Klatman, Beatrice Vetter, Cathy Haldane, Graham Ogle
-
Denosumab in the treatment of osteoporosis associated with chronic kidney disease Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-16 Adrian Covic, Mugurel Apetrii
-
Women in science: inspiring future generations Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-09
-
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-05 Carel W le Roux, Oren Steen, Kathryn J Lucas, Elena Startseva, Anna Unseld, Anita M Hennige
-
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-05 Yiming Mu, Xiaolei Bao, Freddy G Eliaschewitz, Morten Rix Hansen, Bom Taeck Kim, Anna Koroleva, Ronald C W Ma, Tao Yang, Ning Zu, Ming Liu
-
Glucagon—a new player in weight management therapeutics? Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-05 Stephen C Bain, David M Williams
-
GLP-1 analogue therapy for obesity in people from Asia Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-05 Bernard Khoo, Tricia M-M Tan
-
A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-29 Ken K Y Ho, Maria Fleseriu, John Wass, Laurence Katznelson, Gerald Raverot, Andrew S Little, Justo P Castaño, Martin Reincke, M Beatriz Lopes, Ursula B Kaiser, Philippe Chanson, Mônica Gadelha, Shlomo Melmed
No comprehensive classification system that guides prognosis and therapy of pituitary adenomas exists. The 2022 WHO histopathology-based classification system can only be applied to lesions that are resected, which represent few clinically significant pituitary adenomas. Many factors independent of histopathology provide mechanistic insight into causation and influence prognosis and treatment of pituitary
-
PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-02 Michael J Koren, Olivier Descamps, Yoshiki Hata, Ellen Margo Hengeveld, G Kees Hovingh, Ignatios Ikonomidis, Maria D Radu Juul Jensen, Irene Hedelund Langbakke, Fabrice M A C Martens, Anette Luther Søndergaard, Adam Witkowski, Wolfgang Koenig
Background Currently available injectable drugs that target proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce serum LDL cholesterol and improve cardiovascular outcomes. This phase 2 study assessed NNC0385-0434, an oral PCSK9 inhibitor, in individuals receiving oral lipid-lowering therapy. Methods In this randomised, double-blind, placebo-controlled and active-controlled trial, 42 research
-
An anti-PCSK9 pill a day to keep cholesterol away: next steps? Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-02 Gerald F Watts
Abstract not available
-
Air pollution exposure and cardiometabolic risk Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-02-02 Sanjay Rajagopalan, Robert D Brook, Pedro R V O Salerno, Brendan Bourges-Sevenier, Philip Landrigan, Mark J Nieuwenhuijsen, Thomas Munzel, Salil V Deo, Sadeer Al-Kindi
The Global Burden of Disease assessment estimates that 20% of global type 2 diabetes cases are related to chronic exposure to particulate matter (PM) with a diameter of 2·5 μm or less (PM2·5). With 99% of the global population residing in areas where air pollution levels are above current WHO air quality guidelines, and increasing concern in regard to the common drivers of air pollution and climate
-
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-29
Abstract not available
-
TB Joshua and his megachurch: fake medical miracles and abuse in Nigeria Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-29 Talha Burki
Abstract not available
-
The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-23 Jamie Hartmann-Boyce, Patrick Highton, Karen Rees, Igho Onakpoya, Jana Suklan, Ffion Curtis, Lauren O'Mahoney, Elizabeth Morris, Laura Kudlek, Jessica Morgan, Rosie Lynch, Sanjana Marpadga, Samuel Seidu, Kamlesh Khunti
The COVID-19 pandemic triggered disruptions to health care and lifestyles that could conceivably impact diabetes management. We set out to identify the impact of disruptions caused by COVID-19 on clinical outcomes in people with diabetes. We performed a systematic review of the available literature in the MEDLINE and OVID databases from Jan 1, 2020, to June 7, 2023, and included 138 studies (n>1 000 000
-
The price of health Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-23
Abstract not available
-
Association of glycaemic index and glycaemic load with type 2 diabetes and related conditions in prospective studies Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-23 Gabriele Riccardi, Olga Vaccaro
Abstract not available
-
Anti-obesity drugs, eating disorders, and thinness among Japanese young women Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-23 Shotaro Kinoshita, Taishiro Kishimoto
Abstract not available
-
Rafik Jacob: Caring for the most vulnerable Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-23 Talha Burki
Abstract not available
-
Correction to Lancet Diabetes Endocrinol 2023; 11: 42–57 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-23
Abstract not available
-
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-23 David J A Jenkins, Walter C Willett, Salim Yusuf, Frank B Hu, Andrea J Glenn, Simin Liu, Andrew Mente, Victoria Miller, Shrikant I Bangdiwala, Hertzel C Gerstein, Sabina Sieri, Pietro Ferrari, Alpa V Patel, Marjorie L McCullough, Loïc Le Marchand, Neal D Freedman, Erikka Loftfield, Rashmi Sinha, Xiao-Ou Shu, Mathilde Touvier, Wanning Yang
Background There is debate over whether the glycaemic index of foods relates to chronic disease. We aimed to assess the associations between glycaemic index (GI) and glycaemic load (GL) and type 2 diabetes, cardiovascular disease, diabetes-related cancers, and all-cause mortality. Methods We did a meta-analysis of large cohorts (≥100 000 participants) identified from the Richard Doll Consortium. We
-
The fight to put food on the table: from past to present | Pen Vogler, Stuffed: A History of Good Food and Hard Times in Britain, Atlantic Books (2023), p. 453, £22·00, ISBN: 9781838955748 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-05 Talha Burki
Abstract not available
-
Better testing and labelling of drugs for people with obesity Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-04 Talha Burki
Abstract not available
-
The role of medical students in humanitarian responses to armed conflict Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-01-03 Ji Won Susie Yoo, Rahul D Barmanray
Abstract not available
-
Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-19 Jane Speight, Elizabeth Holmes-Truscott, Matthew Garza, Renza Scibilia, Sabina Wagner, Asuka Kato, Victor Pedrero, Sonya Deschênes, Susan J Guzman, Kevin L Joiner, Shengxin Liu, Ingrid Willaing, Katie M Babbott, Bryan Cleal, Jane K Dickinson, Jennifer A Halliday, Eimear C Morrissey, Giesje Nefs, Shane O'Donnell, Anna Serlachius, Timothy C Skinner
People with diabetes often encounter stigma (ie, negative social judgments, stereotypes, prejudice), which can adversely affect emotional, mental, and physical health; self-care, access to optimal health care; and social and professional opportunities. To accelerate an end to diabetes stigma and discrimination, an international multidisciplinary expert panel (n=51 members, from 18 countries) conducted
-
Analysis of type 2 diabetes heterogeneity with a tree-like representation: insights from the prospective German Diabetes Study and the LURIC cohort Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-21 Martin Schön, Katsiaryna Prystupa, Tim Mori, Oana P Zaharia, Kálmán Bódis, Maria Bombrich, Clara Möser, Iryna Yurchenko, Yuliya Kupriyanova, Klaus Strassburger, Pavel Bobrov, Anand T N Nair, Gidon J Bönhof, Alexander Strom, Graciela E Delgado, Sema Kaya, Rainer Guthoff, Norbert Stefan, Andreas L Birkenfeld, Hans Hauner, Robert Wagner
Background Heterogeneity in type 2 diabetes can be represented by a tree-like graph structure by use of reversed graph-embedded dimensionality reduction. We aimed to examine whether this approach can be used to stratify key pathophysiological components and diabetes-related complications during longitudinal follow-up of individuals with recent-onset type 2 diabetes. Methods For this cohort analysis
-
Aspirin and diabetes prevention among healthy older adults—practice-changing or hypothesis-generating? Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-21 John W Ostrominski, Vanita R Aroda
Abstract not available
-
Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-21 Sophia Zoungas, Zhen Zhou, Alice J Owen, Andrea J Curtis, Sara E Espinoza, Michael E Ernst, Robyn L Woods, Suzanne G Orchard, John J McNeil, Anne M Murray, Mark R Nelson, Christopher M Reid, Joanne Ryan, Rory Wolfe
Background Inflammation has been implicated in the pathogenesis of diabetes. This study investigated the randomised treatment effect of low-dose aspirin on incident type 2 diabetes and fasting plasma glucose (FPG) concentrations among older adults. Methods ASPREE was a double-blind, placebo-controlled trial of daily oral low-dose aspirin. The study population included community-dwelling individuals
-
Advancing precision medicine in type 2 diabetes Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-21 Jose C Florez
Abstract not available
-
From research to policy: still a long way to go Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-19
Abstract not available
-
Enhancing global access to diabetes medicines: policy lessons from the HIV response Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-18 Felix Teufel, Caroline A Bulstra, Justine I Davies, Mohammed K Ali
Abstract not available
-
Correction to Lancet Diabetes Endocrinol 2023; 11: 915–25 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-11
Abstract not available
-
Empagliflozin in chronic kidney disease: nephroprotection is independent of albuminuria, primary kidney disease, and baseline eGFR Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-04 Carmine Zoccali, Francesca Mallamaci
Abstract not available
-
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-04 Kausik K Ray, Stephen J Nicholls, Na Li, Michael J Louie, Danielle Brennan, A Michael Lincoff, Steven E Nissen
Background Statins reduce LDL cholesterol and cardiovascular events among those with or without diabetes but have been reported to increase new-onset diabetes. The CLEAR Outcomes trial demonstrated that bempedoic acid reduced the risk of major adverse cardiovascular events among statin-intolerant patients at high cardiovascular risk. In this prespecified analysis, our dual aims were to evaluate the
-
New clarity for managing statin intolerance in diabetes Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-04 Robert A Hegele
Abstract not available
-
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-04
Background The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods EMPA-KIDNEY, a randomised, controlled
-
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-04
Background Sodium–glucose co-transporter-2 (SGLT2) inhibitors reduce progression of chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range of patients. However, their effects on kidney disease progression in some patients with chronic kidney disease are unclear because few clinical kidney outcomes occurred among such patients in the completed trials. In particular
-
Vitamin D supplements for fracture prevention in schoolchildren in Mongolia: analysis of secondary outcomes from a multicentre, double-blind, randomised, placebo-controlled trial Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-01 Davaasambuu Ganmaa, Polyna Khudyakov, Uyanga Buyanjargal, Enkhtsetseg Tserenkhuu, Sumiya Erdenenbaatar, Chuluun-Erdene Achtai, Narankhuu Yansanjav, Baigal Delgererekh, Munkhzaya Ankhbat, Enkhjargal Tsendjav, Batbayar Ochirbat, Badamtsetseg Jargalsaikhan, Davaasambuu Enkhmaa, Adrian R Martineau
Background Vitamin D supplementation has been shown to increase total hip areal bone mineral density in healthy children and adolescents. We aimed to investigate whether supplementing schoolchildren living in Mongolia with weekly vitamin D3 for 3 years affected fracture risk. Methods We did a multicentre, double-blind, randomised, placebo-controlled trial across 18 public schools in Ulaanbaatar, Mongolia
-
Mendelian randomisation at 20 years: how can it avoid hubris, while achieving more? Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-01 George Davey Smith, Shah Ebrahim
Abstract not available
-
Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-01
Background Randomised trials of vitamin D supplementation for cardiovascular disease and all-cause mortality have generally reported null findings. However, generalisability of results to individuals with low vitamin D status is unclear. We aimed to characterise dose-response relationships between 25-hydroxyvitamin D (25[OH]D) concentrations and risk of coronary heart disease, stroke, and all-cause
-
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-01
Abstract not available
-
The role of vitamin D in paediatric bone health Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-01 John M Pettifor, Kebashni Thandrayen
Abstract not available
-
Screening type 1 diabetes and celiac disease by law Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-12-01 Emanuele Bosi, Carlo Catassi
Abstract not available
-
South Africa to produce insulin for Africa in 2024 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-11-28 Munyaradzi Makoni
Abstract not available
-
Correction to Lancet Diabetes Endocrinol 2023; 11: 905–14 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-11-28
Abstract not available
-
Correction to Lancet Diabetes Endocrinol 2023; 11: 942–54 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-11-28
Abstract not available
-
Challenges in implementing nationwide epidemiological studies on metabolic non-communicable diseases in low-income and middle-income countries Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-11-21 Ranjit Mohan Anjana, Nirmal Elangovan, Rajendra Pradeepa, Mohan Deepa, Ranjit Unnikrishnan, Viswanathan Mohan
Abstract not available
-
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-11-21 Yan Xie, Ziyad Al-Aly
Abstract not available
-
Iodine status in Iran: from deficient to replete Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-11-21 Fereidoun Azizi, Hossein Delshad, Mehdi Hedayati, Parvin Mirmiran
Abstract not available
-
Correction to Lancet Diabetes Endocrinol 2023; 11: 798–810 Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-11-23
Abstract not available
-
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-11-21 Ali Ahmed, Stefan D Anker, Javed Butler, George L Bakris, Deepak L Bhatt, Gregg C Fonarow, Milton Packer
Abstract not available
-
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-11-21 Mirac Vural Keskinler, Ozge Telci Caklili, Aytekin Oguz
Abstract not available
-
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2023-11-21 Antonio Ceriello, Francesco Prattichizzo, Cesare Celeste Berra, Augusto Enrique Caballero
Abstract not available